Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include de
EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO Phase 1/2 combination study with pembrolizumab in 1L R/M HNSCC on track to be reported in the fourth quarter of 2026 Completed private placement financing for up to $114 million, providing approximately $50 million in upfront gross proceeds to support additional patient follow-up Upfront proceeds from the private placement, together with existing cash, extended the Company’s cash runway into the second quarter of 2027 BOSTON, August 13, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-...
Source
Exhibit EX-99.1
0001193125-26-347911
Filed August 13, 2026 at 11:42 AM UTC. The figures above are from the audited statements, not from this release.